Latest News & Features
Americas
The US Food and Drug Administration yesterday granted Teva approval for the first generic version of EpiPen, an autoinjector pen used for the emergency treatment of allergic reactions. 17 August 2018
Americas
An addiction treatment facility has accused another organisation of exploiting vulnerable individuals by providing misleading information containing trademarked names on its websites. 16 August 2018
Americas
Robert DeBerardine was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports. 16 August 2018
Americas
Pfizer has entered into a multi-year collaboration with immunotherapy company BioNTech to develop messenger ribonucleic acid-based vaccines for influenza. 16 August 2018
Americas
Padmanabh Bhatt was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports. 15 August 2018
Americas
A patent dispute over a generic version of Purdue Pharma’s drug OxyContin (oxycodone), which is used to treat moderate to severe pain, has come to an end. 15 August 2018
Asia-Pacific
Japan-based Astellas Pharma has acquired Quethera, a UK-headquartered gene therapy company focused on developing treatments for ocular disorders. 15 August 2018
Americas
Medical technology company Biocompatibles UK last week withdrew its oppositions to two trademarks applied for by Pfizer, four months after settlement negotiations. 14 August 2018
article
Roy Waldron was selected in the LSIPR 50 2018 publication for his influence on the life sciences industry. He featured in the legal section, as LSIPR reports. 14 August 2018
Big Pharma
Following a CJEU decision in July, and with two more cases on the horizon, Joel Beevers and Michael Pears of Potter Clarkson report on whether an active ingredient (or combination of active ingredients) is ‘protected by a basic patent’, as required for a supplementary protection certificate. 14 August 2018